Agreed. Toooooooo much expectation around the IND app and far tooooo unrealistic timelines thrown about. Of course, one can argue that is the mismanagement of the company. I don't. This is a fledgling startup that is trying to get footing. Their focus, and rightly so, is to get to clinical trials ASAP and let the pps cards fall where they may. JMHO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.